Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06855498 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | PHASE3 | RECRUITING | 600 | — | — | Feb 28, 2025 | Feb 28, 2028 | Jun 1, 2026 | 317 | United States, Argentina +18 |
| NCT06212999 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | PHASE3 | ACTIVE NOT_RECRUITING | 617 | — | — | Jan 30, 2024 | Dec 26, 2026 | Mar 23, 2026 | 165 | United States, Australia +15 |
| NCT05620836 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | PHASE3 | COMPLETED | 619 | — | — | Feb 22, 2023 | Nov 21, 2025 | Jan 9, 2026 | 101 | United States, Australia +9 |
| NCT05620823 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | PHASE3 | COMPLETED | 608 | — | — | Dec 19, 2022 | Dec 23, 2025 | Feb 10, 2026 | 104 | United States, Austria +10 |
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | PHASE2 | RECRUITING | 40 | — | — | Feb 2, 2026 | Mar 25, 2028 | May 27, 2026 | 29 | United States, Canada |
Adverse events either reported for the first time in this Protocol or any AE ongoing and defined as treatment-emergent from the parent Protocol.
HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
| Arm | Type | Description |
|---|---|---|
| povorcitinib | EXPERIMENTAL | Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled. |
| Cohort A | EXPERIMENTAL | Povorcitinib at the protocol-defined dose strength based on cohort assignment. |
| Cohort B | EXPERIMENTAL | Povorcitinib at the protocol-defined dose strength based on cohort assignment. |
| Cohort C | EXPERIMENTAL | Povorcitinib at the protocol-defined dose strength based on cohort assignment. |
| Povorcitinib Dose A | EXPERIMENTAL | Participants will receive Povorcitinib Dose A for 54 weeks. |
| Povorcitinib Dose B | EXPERIMENTAL | Participants will receive Povorcitinib Dose B for 54 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks. |
| Name | Type | Description |
|---|---|---|
| povorcitinib | DRUG | Study drug will be taken orally as defined by the protocol. |
| Placebo | DRUG | Oral, Tablet |
Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment. * Received clinical benefit from ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Lutikizumab, Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib, povorcitinib, Ruxolitinib, Vehicle |
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | secukinumab, Remibrutinib Dose A, Remibrutinib Dose B, CFZ533, LYS006 |
| MoonLake Immunotherapeutics Class A | MLTX | 4 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig, SAR445399 |
| Insmed Incorporated | INSM | 1 | PHASE2 | Brensocatib |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Eltrekibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |